US6168799B1 - β-D-glucan topical composition - Google Patents

β-D-glucan topical composition Download PDF

Info

Publication number
US6168799B1
US6168799B1 US09/231,311 US23131199A US6168799B1 US 6168799 B1 US6168799 B1 US 6168799B1 US 23131199 A US23131199 A US 23131199A US 6168799 B1 US6168799 B1 US 6168799B1
Authority
US
United States
Prior art keywords
glucan
derived
topical composition
cereal
wounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/231,311
Inventor
Barbara K. Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STELLEN MEDICAL LLC
Original Assignee
Brennen Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brennen Medical Inc filed Critical Brennen Medical Inc
Priority to US09/231,311 priority Critical patent/US6168799B1/en
Application granted granted Critical
Publication of US6168799B1 publication Critical patent/US6168799B1/en
Assigned to BRENNEN MEDICAL, LLC reassignment BRENNEN MEDICAL, LLC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: BRENNEN MEDICAL, INC.
Assigned to STELLEN MEDICAL, LLC reassignment STELLEN MEDICAL, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: STELLEN SCIENCES, LLC
Assigned to STELLEN SCIENCES, LLC reassignment STELLEN SCIENCES, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BRENNEN MEDICAL, LLC
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin

Definitions

  • This invention relates generally to topical compositions for the treatment of superficial and partial thickness burns and wounds of the skin and mucosa. More particularly, the invention pertains to formulations of topical creams and gels providing cleansing, moisturizing, soothing and anti-pruritic activity for topical therapeutic treatment of wounds and burns and other skin loss injuries and conditions.
  • glucans A group of complex polysaccharides known as glucans are found in the cell walls of yeast and bacteria. Though the structures of the microbial-derived glucans have not been completely elucidated, they are known to include long-chain carbohydrate polymers composed solely of ⁇ -D-glucan residues with 1,3 linkages or a combination of 1,3- and 1,6-linkages. In the cell walls of the yeast Saccharomyces cerevisiae, the glucans may also be associated with mannan, another complex polysaccharide.
  • yeast-derived 1,3-glucan activates macrophages, including phages with immunological activity against tumor growth.
  • the 1,6-glucans were found to be inactive relative to macrophages. Such is reported by Di Luzio et al. in THE MACROPHAGE IN NEOPLASIA, Mary A. Fink, editor, 1976, Academic Press, New York, pp 181-182.
  • a topical healing unguent is needed for treatment of burns and wounds of the skin and mucosa where a wound dressing is not indicated.
  • the invention comprises a multi-purpose topical composition for application to the skin and mucosa. It is intended for use as a topically applied cream or gel to provide cleansing and soothing relief of superficial and partial thickness burns, as a moisturizer to enhance water retention of the stratum corneum, and to relieve the itching associated with hypertrophic or keloid scarring.
  • the active ingredient of the topical composition of the invention is being investigated as a possible biological response modifier and macrophage stimulant.
  • the primary active component of the topical composition is cereal-derived ⁇ -D-Glucan, chemically comprising a large number of glucopyranosyl units determined to be linked by (1-3) and (1-4) linkages.
  • the preferred active agent is ⁇ -D-Glucan derived from oats, although the glucans from barley, wheat and/or other cereal grains may be used for the topical composition, provided the (1-4) (1-3) ⁇ -D-Glucan can be extracted economically.
  • composition of the topical cream of the invention comprises the following, where the indicated concentration of each component is uniformly given as a percentage of the total of all components:
  • cereal-derived ⁇ -D-Glucan active agent
  • active agent about 0.5-15 w/w % ointment base about 10-20 w/w % humectant(s) about 2-6 w/w % suspending/viscosity increasing agent(s) about 0.01-8.0 w/w % stiffening agent(s) about 0.5-6 w/w % emulsifying/solubilizing agent(s) about 0.1-8 w/w % antimicrobial agent(s) about 0.1-2 w/w % plasticizer(s) about 5-15 w/w % solvent(s) balance
  • glycerol may serve both as a solvent and a plasticizer
  • propylene glycol may serve as a solvent, humectant and plasticizer.
  • a general formulation for a gel composition of the invention is:
  • cereal derived ⁇ -D-Glucan (active agent) about 0.5-15 w/w % water about 80-98 w/w % suspending/viscosity increasing agent(s) about 0.5-8 w/w % emulsifying/solubilizing agent(s) about 0-5 w/w % antimicrobial agent(s) about 0.05-1 w/w %
  • the cereal-derived ⁇ -D-Glucan in this composition is significantly different from glucans obtained from other sources, including ⁇ -D-Glucans derived from yeast such as Saccharomyces cerevisiae and bacteria such as Cellulomonas flavigena.
  • the primary source of ⁇ -Glucan has historically been yeast and bacterial cells.
  • the cereal-derived (1-4)(1-3) ⁇ -D-glucan useful in the invention is distinctive from microbial-derived glucans which have all (1-3) linkages or primarily (1-3) linkages with a few (1-6) linkages.
  • the molecular weight of the mixed-linkage cereal-derived ⁇ -D-Glucan used in this invention is much greater than that of the microbial-derived glucans.
  • FIG. 1 is a drawing of a generallized chemical structure of microbe-derived (1-3) ⁇ -D-glucan used in a prior art composition
  • FIG. 2 is a drawing of a generallized chemical structure of microbe-derived (1-3)(1-6) ⁇ -D-glucan;
  • FIG. 3 is a drawing of a proposed generallized chemical structure of mixed-linkage cereal-derived (1-3)(1-4) ⁇ -D-glucan used in a topical composition of the invention.
  • compositions for multi-purpose topical treatment wherein the active ingredient is a cereal-derived ⁇ -D-glucan, identified herein as “CDG”.
  • CDG cereal-derived ⁇ -D-glucan
  • the invention pertains to various topical compositions including a solvent base varying from essentially all water to essentially all oil.
  • the invention includes topical compositions variously known as unguents, creams, gels, emollients, lotions and oils, each with a generally characteristic solvent composition, and having a form ranging from liquid to semisolid.
  • ⁇ -glucans comprise a large group of high molecular weight polymers containing glucopyranosyl units in ⁇ -linked chains.
  • ⁇ -glucans are found in essentially all living cells which are enclosed by cell walls, with considerable structural variation dependent on source. They are highly unbranched homopolysaccharides and isomerically diaposed to alpha-D-glucan (e.g. starch) which is typically non-functional as a structural support component of the cell.
  • glucans derived from microbes have been generally characterized as essentially comprising (1-3)-linked chains of glucopyranosyl units.
  • yeast-derived glucans having primarily (1-3)-linkages with a relatively small number of (1-6)-linkages (FIG. 2) have been identified.
  • Yeast-derived glucan polymers are often associated with mannose, and typically have a helically coiled chain shape.
  • Glucans derived from cereal grains as shown in FIG. 3, have (1-3) and (1-4) linkages and generally have a linear or kinked linear chain.
  • Cereal-derived glucan may be characterized as follows:
  • CDG is a long chain, unbranched polysaccharide which typically comprises about 3-4 percent of oat and barley grains.
  • the CDG concentration is greater, e.g. 7-10 percent, in the milled bran fraction of oats.
  • CDG is found in the endosperm and aleurone cell walls of most cereal grains.
  • the microbe-derived glucans occur in the cell wall of the yeast or bacteria.
  • CDG is a mixed-linkage molecule containing about 70 percent (1-4)-linkages and about 30 percent (1-3)-linkages.
  • the (1-3)-linked units mostly occur singly whereas the (1-4)-linked units typically occur in groups of three or four glucopyranosyl units.
  • the resultant structure is a series of short runs of 3 or 4 (1-4)-linked glucopyranosyl units, adjacent runs connected by (1-3) linkages.
  • the frequencies of the groups of three 20 (cellotriosyl) and four (cellotetraosyl) glucopyranosyl units also tend to be characteristic of the source, being affected by cereal variety, tissue age, and stage of maturity oat-derived CDG typically has more of the groups of three consecutive (1-4)-linked glucopyranosyl units than does barley-derived CDG.
  • the ratio of trisaccharide to tetrasaccharide groups is about 2:1 for oats and closer to 3:1 for barley.
  • CDG differs from microbe-derived glucans, which have all (1-3)-linkages or mostly (1-3)-linkages with some (1-6)-linkages.
  • CDG is a linear molecule, while yeast-derived glucan forms a helical shape.
  • the degree of polymerization of CDG is in the range of about 1200-1800.
  • yeast-derived ⁇ -D-glucan has a much lower degree of polymerization, i.e. about 60-80.
  • Cellulose the primary constituent of plant cell walls, has all ⁇ (1-4) linkages and a degree of polymerization of about 10,000 to 15,000.
  • CDG forms viscous solutions in warm water.
  • yeast-derived glucan is insoluble in water but dispersible in aqueous systems.
  • CDG occurs within the grain with a fairly broad range of MW, i.e. about 200,000 to 700,000. The molecular weight is believed to be dependent upon the grain species, grain source, glucan extraction conditions and particular laboratory. Microbe-derived glucan has a much lower molecular weight, in the range of about 10,000 to 14,000. Cellulose has a molecular weight of about 700,000.
  • CDG as a food component has been studied extensively by various researchers; studies have included the use of CDG in regulation of glucose metabolism, hypoglycemic response, reduction in serum cholesterol, and the like.
  • CDG is much more like cellulose than are the microbial-derived glucans.
  • Each of the components of the new composition serves a particular function or functions, and is available in purities conducive to use in the particular applications.
  • a component may comprise United States Pharmacia (USP), National Formulary (NF), or other purified grade appropriate for topical use on burns and wounds on the skin.
  • the components of the cream formulation include:
  • an ointment base preferably white petrolatum.
  • An alternative but somewhat less desirable substance for this purpose is lanolin.
  • a solvent primarily or entirely water. Additional solvents which may be added at generally lower concentrations include natural oils such as cod liver oil, mineral oil, etc., and glycerol or propylene glycol.
  • the water content of the cream formulation is at least about 50 percent.
  • a plasticizer preferably glycerol.
  • Propylene glycol or another glycol may also be used as a plasticizer.
  • a humectant preferably propylene glycol.
  • suspending or viscosity enhancement agent such as carrageenen.
  • Other possible exemplary agents include polyvinyl alcohol, xanthan gum, agarose, alginate, guar gum, Carbopol 940TM carbomer (B.F. Goodrich), and carboxymethylcellulose (CMC), as well as mixtures thereof.
  • a variation in the concentration of suspending agents is compensated by varying the water (solvent) concentration.
  • an emulsifying or solubilizing agent or agents emulsifying or solubilizing agent or agents.
  • agents are sodium lauryl sulfate and triethanolamine. In the preferred formulation, a combination of sodium lauryl sulfate and triethanolamine is used.
  • a stiffening agent preferably cetyl alcohol (hexadecanoic acid). Paraffin may also be used.
  • an antimicrobial agent preferably one or more parabens.
  • the paraben may be methylparaben, propylparaben, ethylparaben, butyl paraben, or mixtures thereof.
  • Other possible antimicrobial agents are imidurea, benzoic acid and benzoic alcohol.
  • a preferred formulation of the cream composition of the invention is:
  • Cereal-derived ⁇ -D-glucan about 0.5-15 w/w % Petrolatum (white) about 0.5-15 w/w % Glycerol about 5-15 w/w % Propylene Glycol about 2-6 w/w % Cetyl Alcohol (Hexadecanoic Acid) about 0.5-6 w/w % Triethanolamine about 0.1-5 w/w % Sodium Lauryl Sulfate about 0.1-5 w/w % Parabens about 0.01-2 w/w % Carrageenan about 0.01-1.0 w/w % Water balance (at least 50%)
  • a presently most preferred composition of the topical cream is as follows:
  • Cereal-derived ⁇ -D-glucan about 2 w/w percent Petrolatum (white) about 15 w/w percent Glycerol about 10 w/w percent Propylene Glycol about 4 w/w percent Cetyl Alcohol (Hexadecanoic Acid) about 2 w/w percent Triethanolamine about 2 w/w percent Sodium Lauryl Sulfate about 1 w/w percent i-Carrageenan about 0.3 w/w percent Methyl Paraben about 0.2 w/w percent Propyl Paraben about 0.2 w/w percent Xanthan Gum about 0.15 w/w percent Water balance (about 63.15 w/w %)
  • Cereal-derived ⁇ -D-glucan about 2 w/w percent Petrolatum (white) about 15 w/w percent Glycerol about 10 w/w percent Propylene Glycol about 4 w/w percent Cetyl Alcohol (Hexadecanoic Acid) about 2 w/w percent Triethanolamine about 2 w/w percent Sodium Lauryl Sulfate about 1 w/w percent Parabens about 0.25 w/w percent Carrageenan about 0.1 w/w percent Water balance (about 62.75 w/w %)
  • a 100 g batch of a topical cream of the invention was prepared having the following ingredients, given as g per 100 g total cream composition:
  • a stock solution of 4% ⁇ -D-glucan was prepared by dissolving 4.0 g of purified oat-derived ⁇ -D-glucan (powder) in 96 ml of distilled water in an autoclave bottle. The solution was stirred vigorously and then autoclaved at 121° C. with stirring until the glucan was fully dissolved.
  • the once-homogenized cream composition was cooled to about 50° C. and homogenized a second time at the same speed and time conditions.
  • the cream composition was then dispensed into individual containers and cooled to room temperature.
  • the cream composition When topically applied, the cream composition had a desired tactile soothing, non-greasy feeling with a consistency like that of whipped cream.
  • the cream composition provided very good skin moisturization and emollience.
  • a fat free, water soluble version of the cream may be provided.
  • the levels of Beta D-glucan and the other water soluble components world be increased, and no petrolatum base would be present.
  • concentration ranges from the examples given above would remain applicable.
  • a useful gel composition of the invention including the active ingredient, cereal-derived ⁇ -D-glucan, is as follows:
  • Cereal-derived ⁇ -D-glucan about 0.5-15% Water about 80-98% Polyvinyl alcohol about 0.5-4% Xanthan gum and/or CMC about 0.5-4% Other suspending agent(s) about 0-4% Antimicrobial agent(s) about 0.1-1%
  • suspending/viscosity increasing agent(s) which may be added include carrageenan, agarose, alginate, Carbomer 940TM thickener, and guar gum, at concentrations of each additional agent at about 0.01-4%.
  • carrageenan agarose
  • alginate alginate
  • Carbomer 940TM thickener a suspending/viscosity increasing agent which may be added
  • guar gum guar gum
  • concentrations of each additional agent at about 0.01-4%.
  • the use of xanthan gum and/or CMC is particularly advantageous for producing a clear colorless gel.
  • one or more emulsifying/solubilizing agents such as triethanolamine may be added at about 2 percent each.
  • a chelating agent such as ethylene-diaminetetraacetic acid (EDTA) may be added at about 0.1-0.5 percent, generally as its tetrasodium salt.
  • EDTA ethylene-diaminetetraacetic acid
  • a most preferred embodiment of the gel composition comprises:
  • Cereal-derived ⁇ -D-glucan about 2.0 w/w % Polyvinyl alcohol about 2.0 w/w % Triethanolamine about 2.0 w/w % Carboxymethylcellulose (CMC) about 2.0 w/w % Additional suspending agent about 0-4 w/w % EDTA about 0.2 w/w % Methyl Paraben about 0.2 w/w % Propyl Paraben about 0.2 w/w % Water (at least 80%) balance
  • a preferred additional suspending agent is CarbopolTM 940 carbomer, added at about 0.5 percent.
  • a 100 g batch of a gel composition of the invention was prepared having the following ingredients:
  • the gel composition produced by this method had a soothing feeling with high moisturizing and emollient properties.
  • An oil-based topical composition containing cereal-derived ⁇ -D-glucan may be formulated.
  • the solvent of the basic cream or gel formulation is changed to be primarily an oil or mixture of oils.
  • the water content is reduced to compensate for the increased concentrations of oil(s).
  • the other ingredients may remain the same or be varied as desired.
  • the solvent may comprise, for example, all oil(s), or a mixture of oil and water, where the oil fraction is generally greater than the water fraction.
  • topical compositions for treatment of burns and wounds are, at this time, the cream and gel formulations.
  • the composition may be topically applied to the area of damaged tissue.
  • the glucan containing cream or (gel of the invention provides a soothing emmolient, moisturizing, anti-pruritic and biologically-derived dermal protection to assist during the skin's recuperative process.
  • the treatment comprises:
  • the method is useful for management of scars due to burns, wounds or surgery, and the cream or gel is topically applied to the affected hypertrophic or keloid scar.
  • the topical composition provides a more rapid healing of burns or wounds, moisturizing relief for dryness and skin irritation, and a reduction in pruritus.
  • the active ingredient, cereal-derived ⁇ -D-glucan may also be a biological response modifier, i.e. a macrophage stimulator.

Abstract

A topical composition for healing treatment of burns and wounds and scarring therefrom has as the active ingredient cereal-derived (1-3) (1-4) beta-D-glucan at about 0.5-15 w/w percent. The composition may be formulated in various forms with creams and gels being preferred for application to the skin.

Description

This is a continuation of application Ser. No. 08/957,529, filed Oct. 24, 1997 now U.S. Pat. No. 5,980,918.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to topical compositions for the treatment of superficial and partial thickness burns and wounds of the skin and mucosa. More particularly, the invention pertains to formulations of topical creams and gels providing cleansing, moisturizing, soothing and anti-pruritic activity for topical therapeutic treatment of wounds and burns and other skin loss injuries and conditions.
2. State of the Art
A group of complex polysaccharides known as glucans are found in the cell walls of yeast and bacteria. Though the structures of the microbial-derived glucans have not been completely elucidated, they are known to include long-chain carbohydrate polymers composed solely of β-D-glucan residues with 1,3 linkages or a combination of 1,3- and 1,6-linkages. In the cell walls of the yeast Saccharomyces cerevisiae, the glucans may also be associated with mannan, another complex polysaccharide.
Studies have indicated that yeast-derived 1,3-glucan activates macrophages, including phages with immunological activity against tumor growth. The 1,6-glucans were found to be inactive relative to macrophages. Such is reported by Di Luzio et al. in THE MACROPHAGE IN NEOPLASIA, Mary A. Fink, editor, 1976, Academic Press, New York, pp 181-182.
In U.S. Pat. No. 5,158,772 of Davis, the incorporation of a microbial-derived beta-1,3-glucan-type polysaccharide in a topical composition is disclosed. The polysaccharide is produced by a bacterial microorganism known as Cellulomonas flavigena. The functions of the polysaccharide in the topical composition are described as three-fold, i.e. (a) its effectiveness as a water-holding agent by which it controls the fluidity, appearance and “feel” of a composition, (b) its viscosity raising effect, and (c) its ability to suspend other cosmetic and therapeutic agents such as dyes, drugs, germicides, anesthetics, etc. as a carrier.
In a U.S. patent application of Williams and Lawin, bearing Ser. No. 08/423,838 and commonly assigned with this application, a mesh matrix wound dressing is disclosed which incorporates cereal-derived β-D-glucan and collagen in a cast burn dressing.
A topical healing unguent is needed for treatment of burns and wounds of the skin and mucosa where a wound dressing is not indicated.
SUMMARY OF THE INVENTION
The invention comprises a multi-purpose topical composition for application to the skin and mucosa. It is intended for use as a topically applied cream or gel to provide cleansing and soothing relief of superficial and partial thickness burns, as a moisturizer to enhance water retention of the stratum corneum, and to relieve the itching associated with hypertrophic or keloid scarring.
The active ingredient of the topical composition of the invention is being investigated as a possible biological response modifier and macrophage stimulant.
The primary active component of the topical composition is cereal-derived β-D-Glucan, chemically comprising a large number of glucopyranosyl units determined to be linked by (1-3) and (1-4) linkages. The preferred active agent is β-D-Glucan derived from oats, although the glucans from barley, wheat and/or other cereal grains may be used for the topical composition, provided the (1-4) (1-3) β-D-Glucan can be extracted economically.
As generally formulated, the composition of the topical cream of the invention comprises the following, where the indicated concentration of each component is uniformly given as a percentage of the total of all components:
cereal-derived β-D-Glucan (active agent) about 0.5-15 w/w %
ointment base about 10-20 w/w %
humectant(s) about 2-6 w/w %
suspending/viscosity increasing agent(s) about 0.01-8.0 w/w %
stiffening agent(s) about 0.5-6 w/w %
emulsifying/solubilizing agent(s) about 0.1-8 w/w %
antimicrobial agent(s) about 0.1-2 w/w %
plasticizer(s) about 5-15 w/w %
solvent(s) balance
Some ingredients may have several functions. For example, glycerol may serve both as a solvent and a plasticizer, and propylene glycol may serve as a solvent, humectant and plasticizer.
A general formulation for a gel composition of the invention is:
cereal derived β-D-Glucan (active agent) about 0.5-15 w/w %
water about 80-98 w/w %
suspending/viscosity increasing agent(s) about 0.5-8 w/w %
emulsifying/solubilizing agent(s) about 0-5 w/w %
antimicrobial agent(s) about 0.05-1 w/w %
The cereal-derived β-D-Glucan in this composition is significantly different from glucans obtained from other sources, including β-D-Glucans derived from yeast such as Saccharomyces cerevisiae and bacteria such as Cellulomonas flavigena.
The primary source of β-Glucan has historically been yeast and bacterial cells. However, the cereal-derived (1-4)(1-3) β-D-glucan useful in the invention is distinctive from microbial-derived glucans which have all (1-3) linkages or primarily (1-3) linkages with a few (1-6) linkages. The molecular weight of the mixed-linkage cereal-derived β-D-Glucan used in this invention is much greater than that of the microbial-derived glucans.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a drawing of a generallized chemical structure of microbe-derived (1-3) β-D-glucan used in a prior art composition;
FIG. 2 is a drawing of a generallized chemical structure of microbe-derived (1-3)(1-6) β-D-glucan; and
FIG. 3 is a drawing of a proposed generallized chemical structure of mixed-linkage cereal-derived (1-3)(1-4) β-D-glucan used in a topical composition of the invention.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the invention, new compositions for multi-purpose topical treatment are presented wherein the active ingredient is a cereal-derived β-D-glucan, identified herein as “CDG”. The invention pertains to various topical compositions including a solvent base varying from essentially all water to essentially all oil. The invention includes topical compositions variously known as unguents, creams, gels, emollients, lotions and oils, each with a generally characteristic solvent composition, and having a form ranging from liquid to semisolid.
Compounds classified as β-glucans comprise a large group of high molecular weight polymers containing glucopyranosyl units in β-linked chains. β-glucans are found in essentially all living cells which are enclosed by cell walls, with considerable structural variation dependent on source. They are highly unbranched homopolysaccharides and isomerically diaposed to alpha-D-glucan (e.g. starch) which is typically non-functional as a structural support component of the cell.
As depicted in FIG. 1, glucans derived from microbes have been generally characterized as essentially comprising (1-3)-linked chains of glucopyranosyl units. With the recent advances in test identification methods, yeast-derived glucans having primarily (1-3)-linkages with a relatively small number of (1-6)-linkages (FIG. 2) have been identified. Yeast-derived glucan polymers are often associated with mannose, and typically have a helically coiled chain shape.
The mixed linkage glucan polymers found in cereals are quite different from yeast-derived and bacteria-derived polymers. Glucans derived from cereal grains, as shown in FIG. 3, have (1-3) and (1-4) linkages and generally have a linear or kinked linear chain.
Cereal-derived glucan (CDG) may be characterized as follows:
a. CDG is a long chain, unbranched polysaccharide which typically comprises about 3-4 percent of oat and barley grains. The CDG concentration is greater, e.g. 7-10 percent, in the milled bran fraction of oats.
b. CDG is found in the endosperm and aleurone cell walls of most cereal grains. The microbe-derived glucans occur in the cell wall of the yeast or bacteria.
c. CDG is a mixed-linkage molecule containing about 70 percent (1-4)-linkages and about 30 percent (1-3)-linkages. The (1-3)-linked units mostly occur singly whereas the (1-4)-linked units typically occur in groups of three or four glucopyranosyl units. Thus, the resultant structure is a series of short runs of 3 or 4 (1-4)-linked glucopyranosyl units, adjacent runs connected by (1-3) linkages. The frequencies of the groups of three 20 (cellotriosyl) and four (cellotetraosyl) glucopyranosyl units also tend to be characteristic of the source, being affected by cereal variety, tissue age, and stage of maturity oat-derived CDG typically has more of the groups of three consecutive (1-4)-linked glucopyranosyl units than does barley-derived CDG. The ratio of trisaccharide to tetrasaccharide groups is about 2:1 for oats and closer to 3:1 for barley. CDG differs from microbe-derived glucans, which have all (1-3)-linkages or mostly (1-3)-linkages with some (1-6)-linkages.
d. CDG is a linear molecule, while yeast-derived glucan forms a helical shape.
e. The degree of polymerization of CDG is in the range of about 1200-1800. On the other hand, yeast-derived β-D-glucan has a much lower degree of polymerization, i.e. about 60-80. Cellulose, the primary constituent of plant cell walls, has all β (1-4) linkages and a degree of polymerization of about 10,000 to 15,000.
f. CDG forms viscous solutions in warm water. On the other hand, yeast-derived glucan is insoluble in water but dispersible in aqueous systems.
g. CDG occurs within the grain with a fairly broad range of MW, i.e. about 200,000 to 700,000. The molecular weight is believed to be dependent upon the grain species, grain source, glucan extraction conditions and particular laboratory. Microbe-derived glucan has a much lower molecular weight, in the range of about 10,000 to 14,000. Cellulose has a molecular weight of about 700,000.
h. The use of CDG as a food component has been studied extensively by various researchers; studies have included the use of CDG in regulation of glucose metabolism, hypoglycemic response, reduction in serum cholesterol, and the like.
Thus, in terms of chemical structure and molecular weight, CDG is much more like cellulose than are the microbial-derived glucans.
Each of the components of the new composition serves a particular function or functions, and is available in purities conducive to use in the particular applications. Thus, a component may comprise United States Pharmacia (USP), National Formulary (NF), or other purified grade appropriate for topical use on burns and wounds on the skin.
In addition to cereal-derived β-D-glucan, the components of the cream formulation include:
a. an ointment base, preferably white petrolatum. An alternative but somewhat less desirable substance for this purpose is lanolin.
b. a solvent, primarily or entirely water. Additional solvents which may be added at generally lower concentrations include natural oils such as cod liver oil, mineral oil, etc., and glycerol or propylene glycol. The water content of the cream formulation is at least about 50 percent.
c. a plasticizer, preferably glycerol. Propylene glycol or another glycol may also be used as a plasticizer.
d. a humectant, preferably propylene glycol.
e. a suspending or viscosity enhancement agent, such as carrageenen. Other possible exemplary agents include polyvinyl alcohol, xanthan gum, agarose, alginate, guar gum, Carbopol 940™ carbomer (B.F. Goodrich), and carboxymethylcellulose (CMC), as well as mixtures thereof. A variation in the concentration of suspending agents is compensated by varying the water (solvent) concentration.
f. an emulsifying or solubilizing agent or agents. Exemplary agents are sodium lauryl sulfate and triethanolamine. In the preferred formulation, a combination of sodium lauryl sulfate and triethanolamine is used.
g. a stiffening agent, preferably cetyl alcohol (hexadecanoic acid). Paraffin may also be used.
h. an antimicrobial agent, preferably one or more parabens. The paraben may be methylparaben, propylparaben, ethylparaben, butyl paraben, or mixtures thereof. Other possible antimicrobial agents are imidurea, benzoic acid and benzoic alcohol.
A preferred formulation of the cream composition of the invention is:
Cereal-derived β-D-glucan about 0.5-15 w/w %
Petrolatum (white) about 0.5-15 w/w %
Glycerol about 5-15 w/w %
Propylene Glycol about 2-6 w/w %
Cetyl Alcohol (Hexadecanoic Acid) about 0.5-6 w/w %
Triethanolamine about 0.1-5 w/w %
Sodium Lauryl Sulfate about 0.1-5 w/w %
Parabens about 0.01-2 w/w %
Carrageenan about 0.01-1.0 w/w %
Water balance (at least 50%)
A presently most preferred composition of the topical cream is as follows:
Cereal-derived β-D-glucan about 2 w/w percent
Petrolatum (white) about 15 w/w percent
Glycerol about 10 w/w percent
Propylene Glycol about 4 w/w percent
Cetyl Alcohol (Hexadecanoic Acid) about 2 w/w percent
Triethanolamine about 2 w/w percent
Sodium Lauryl Sulfate about 1 w/w percent
i-Carrageenan about 0.3 w/w percent
Methyl Paraben about 0.2 w/w percent
Propyl Paraben about 0.2 w/w percent
Xanthan Gum about 0.15 w/w percent
Water balance (about 63.15 w/w %)
Another preferred embodiment of the cream composition is as follows:
Cereal-derived β-D-glucan about 2 w/w percent
Petrolatum (white) about 15 w/w percent
Glycerol about 10 w/w percent
Propylene Glycol about 4 w/w percent
Cetyl Alcohol (Hexadecanoic Acid) about 2 w/w percent
Triethanolamine about 2 w/w percent
Sodium Lauryl Sulfate about 1 w/w percent
Parabens about 0.25 w/w percent
Carrageenan about 0.1 w/w percent
Water balance (about 62.75 w/w %)
EXAMPLE A
A 100 g batch of a topical cream of the invention was prepared having the following ingredients, given as g per 100 g total cream composition:
Water 63.15 g/100 g
White Petrolatum, m.p. 38-60° C. 15.0 g/100 g
Glycerol 10.0 g/100 g
Propylene Glycol 4.0 g/100 g
Cereal (oat)-derived β-D-glucan 2.0 g/100 g
Cetyl Alcohol 2.0 g/100 g
Triethanolamine 2.0 g/100 g
Lauryl sulfate 1.0 g/100 g
i-Carrageenan 0.3 g/100 g
Methylparaben 0.2 g/100 g
Propylparaben 0.2 g/100 g
Xanthan Gum 0.15 g/100 g
A stock solution of 4% β-D-glucan was prepared by dissolving 4.0 g of purified oat-derived β-D-glucan (powder) in 96 ml of distilled water in an autoclave bottle. The solution was stirred vigorously and then autoclaved at 121° C. with stirring until the glucan was fully dissolved.
To 50 ml of the stock solution of dissolved β-D-glucan were added the remaining ingredients at the above indicated weights. Additional water was added to bring the components of the mixture to the desired final concentrations. The mixture (at 85-90° C.) was liquified with constant stirring until all ingredients were dissolved and the mixture was homogeneous. The solution was then homogenized in a Polytron homogenizer for 45 seconds at a speed setting of 3.
The once-homogenized cream composition was cooled to about 50° C. and homogenized a second time at the same speed and time conditions. The cream composition was then dispensed into individual containers and cooled to room temperature.
When topically applied, the cream composition had a desired tactile soothing, non-greasy feeling with a consistency like that of whipped cream. The cream composition provided very good skin moisturization and emollience.
Alternatively, a fat free, water soluble version of the cream may be provided. In such a composition, the levels of Beta D-glucan and the other water soluble components world be increased, and no petrolatum base would be present. The concentration ranges from the examples given above would remain applicable.
A useful gel composition of the invention, including the active ingredient, cereal-derived β-D-glucan, is as follows:
Cereal-derived β-D-glucan about 0.5-15%
Water about 80-98%
Polyvinyl alcohol about 0.5-4%
Xanthan gum and/or CMC about 0.5-4%
Other suspending agent(s) about 0-4%
Antimicrobial agent(s) about 0.1-1%
Other suspending/viscosity increasing agent(s) which may be added include carrageenan, agarose, alginate, Carbomer 940™ thickener, and guar gum, at concentrations of each additional agent at about 0.01-4%. The use of xanthan gum and/or CMC is particularly advantageous for producing a clear colorless gel.
In addition, one or more emulsifying/solubilizing agents such as triethanolamine may be added at about 2 percent each.
Furthermore, a chelating agent such as ethylene-diaminetetraacetic acid (EDTA) may be added at about 0.1-0.5 percent, generally as its tetrasodium salt.
Thus, a most preferred embodiment of the gel composition comprises:
Cereal-derived β-D-glucan about 2.0 w/w %
Polyvinyl alcohol about 2.0 w/w %
Triethanolamine about 2.0 w/w %
Carboxymethylcellulose (CMC) about 2.0 w/w %
Additional suspending agent about 0-4 w/w %
EDTA about 0.2 w/w %
Methyl Paraben about 0.2 w/w %
Propyl Paraben about 0.2 w/w %
Water (at least 80%) balance
A preferred additional suspending agent is Carbopol™ 940 carbomer, added at about 0.5 percent.
EXAMPLE B
A 100 g batch of a gel composition of the invention was prepared having the following ingredients:
Water (distilled) 92.9 g/100 g
Cereal (oat)-derived β-D-glucan 2.0 g/100 g
Triethanolamine 2.0 g/100 g
Carboxymethylcellulose (CMC) 1.0 g/100 g
Polyvinyl Alcohol 1.0 g/100 g
Carbopol ™ 940 carbomer(acrylic acid homopolymer) 0.5 g/100 g
Ethylenediaminetetraacetic Acid (EDTA) 0.2 g/100 g
Methylparaben 0.2 g/100 g
Propylparaben 0.2 g/100 g
43.9 g of water (room temperature) was placed in a container and stirred rapidly to produce a vortex at the bottom of the container. The weighed-out carbomer was then sifted into the agitated water until it dissolved completely. The remaining dry ingredients were then added to the container while stirring to achieve a uniform mixture/solution. The appropriate quantity (50.0 g) of the cereal(oat)-derived β-D-glucan stock solution of Example A was added to the container, and the mixture was liquified at 85-90° C. with constant stirring until all ingredients were dissolved and the solution homogeneous. The gel composition was allowed to cool to room temperature, and dispensed into individual containers.
The gel composition produced by this method had a soothing feeling with high moisturizing and emollient properties.
An oil-based topical composition containing cereal-derived β-D-glucan may be formulated. In this composition, the solvent of the basic cream or gel formulation is changed to be primarily an oil or mixture of oils. The water content is reduced to compensate for the increased concentrations of oil(s). The other ingredients may remain the same or be varied as desired. In the oil composition, the solvent may comprise, for example, all oil(s), or a mixture of oil and water, where the oil fraction is generally greater than the water fraction.
However, the preferred forms of topical compositions for treatment of burns and wounds are, at this time, the cream and gel formulations.
In a method of the invention for management of burns and wounds, the composition may be topically applied to the area of damaged tissue. The glucan containing cream or (gel of the invention provides a soothing emmolient, moisturizing, anti-pruritic and biologically-derived dermal protection to assist during the skin's recuperative process.
The treatment comprises:
1. thorough cleansing of the burn area or site of tissue destruction;
2. liberal topical application of the topical composition to the affected area; and
3. repeated application of the composition until healing is complete.
The method is useful for management of scars due to burns, wounds or surgery, and the cream or gel is topically applied to the affected hypertrophic or keloid scar. The topical composition provides a more rapid healing of burns or wounds, moisturizing relief for dryness and skin irritation, and a reduction in pruritus. The active ingredient, cereal-derived β-D-glucan may also be a biological response modifier, i.e. a macrophage stimulator.

Claims (8)

What is claimed is:
1. A method for treating burns and wounds and other skin loss injuries and conditions comprising the step of applying to the affected area of the skin of a patient a topical composition comprising cereal derived β-D-Glucan as an active ingredient to thereby stimulate an immune response in the cells in the affected area of the skin.
2. The method of claim 1 wherein the topical composition comprises one of a cream base, a gel base and an oil base.
3. The method of claim 1 wherein the cereal derived b-D-Glucan is derived from one of barley, oats, and wheat.
4. A method for treating burns and wounds and other skin loss injuries and conditions comprising the step of applying to the affected area of the skin of a patient a topical composition comprising cereal derived β-D-Glucan characterized as (1→3) (1→4) β-D-Glucan as the active ingredient.
5. A method for treating burns and wounds and other skin loss injuries and conditions comprising the steps of:
cleansing thoroughly a wound area of damaged tissue;
applying to the wound area a topical composition comprising a cereal derived β-D-Glucan as the active ingredient to thereby stimulate an immune response in the cells in the wound area; and
repeating the application of the topical composition until healing is complete.
6. A method of treating burns and wounds and other skin loss injuries and conditions comprising the steps of:
cleansing thoroughly a wound area of damaged tissue;
applying a topical composition comprising a cereal derived β-D-Glucan characterized as (1→3)(1→4) β-D-Glucan as the active ingredient; and
applying repeatedly the topical composition until healing is complete.
7. A method for treating burns and wounds and other skin loss injuries and conditions comprising the steps of:
cleansing thoroughly a wound area of damaged tissue;
applying to the wound area a topical composition comprising a cereal derived β-D-Glucan as the active ingredient to thereby stimulate an immune response in the cells in the wound area; and
repeating the application of the topical composition.
8. A method of treating burns and wounds and other skin loss injuries and conditions comprising the steps of:
cleansing thoroughly a wound area of damaged tissue;
applying a topical composition comprising a cereal derived β-D-Glucan characterized as (1→3)(1→4) β-D-Glucan as the active ingredient; and
repeating the application of the topical composition.
US09/231,311 1997-10-24 1999-01-13 β-D-glucan topical composition Expired - Lifetime US6168799B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/231,311 US6168799B1 (en) 1997-10-24 1999-01-13 β-D-glucan topical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/957,529 US5980918A (en) 1997-10-24 1997-10-24 β-D-glucan topical composition
US09/231,311 US6168799B1 (en) 1997-10-24 1999-01-13 β-D-glucan topical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/957,529 Continuation US5980918A (en) 1997-10-24 1997-10-24 β-D-glucan topical composition

Publications (1)

Publication Number Publication Date
US6168799B1 true US6168799B1 (en) 2001-01-02

Family

ID=25499710

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/957,529 Expired - Lifetime US5980918A (en) 1997-10-24 1997-10-24 β-D-glucan topical composition
US09/231,311 Expired - Lifetime US6168799B1 (en) 1997-10-24 1999-01-13 β-D-glucan topical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/957,529 Expired - Lifetime US5980918A (en) 1997-10-24 1997-10-24 β-D-glucan topical composition

Country Status (5)

Country Link
US (2) US5980918A (en)
EP (1) EP1024784A4 (en)
JP (1) JP2001520982A (en)
CA (1) CA2304815A1 (en)
WO (1) WO1999021531A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157143A1 (en) * 1999-09-27 2003-08-21 Klein Barbara K. Immunostimulating coating for surgical devices
DE10214507A1 (en) * 2002-04-02 2003-10-16 Beiersdorf Ag Use of topical composition comprising acarbose or its derivatives to prevent or treat degenerative skin conditions, especially skin irritation, skin inflammation, atopic eczema and neurodermatitis
US20050019876A1 (en) * 1999-10-01 2005-01-27 Incorporated Administrative Agency National Agriculture And Bio-Oriented Research Organization Cellulose produced by filamentous fungi
US20050031674A1 (en) * 2001-12-11 2005-02-10 Ceapro, Inc Cereal beta glucan compositions, methods of preparation and uses thereof
US20060240083A1 (en) * 2000-03-30 2006-10-26 Brennen Medical, Llc Antimicrobial and immunostimulating composition
US20070104858A1 (en) * 2000-02-07 2007-05-10 Granate Seed Limited,a New Zealand corporation Process for extraction of beta-glucan from cereals and products obtained therefrom
KR100832387B1 (en) * 2005-12-02 2008-05-26 주식회사 글루칸 Pharmaceutical Composition for Treatment of Wound and Dermatitis Comprising Glucan as Active Ingredient
WO2010042991A1 (en) * 2008-10-15 2010-04-22 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
US20100190872A1 (en) * 2005-05-05 2010-07-29 Sensient Flavors Inc. Production of beta-glucans and mannans
JP2013155203A (en) * 2006-11-02 2013-08-15 Aureo Co Ltd Agent for promoting healing of living body
GB2536077A (en) * 2014-09-26 2016-09-07 Suavizantes Y Plastificantes Bituminosos S L Formulation for a cosmetic and personal care product and method for production thereof
EP3130609A1 (en) * 2010-11-29 2017-02-15 Biotec Pharmacon ASA Composition comprising a gelling agent plus glucan
CN109568652A (en) * 2018-12-26 2019-04-05 粤肽生物科技(珠海)有限公司 Promote the dressing composition of wound healing
US11384160B1 (en) 2021-07-30 2022-07-12 Tissue repair ltd Method of making a beta glucan compound
US11572420B1 (en) 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
US11701451B1 (en) 2022-03-11 2023-07-18 Carbon Medical Technologies, Inc. Soft tissue filler and methods

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081038C (en) * 1996-09-25 2002-03-20 格雷斯林克有限公司 Beta-glucan products and extration from cereals thereof
US6165994A (en) * 1999-02-08 2000-12-26 Blue Ridge Pharmaceuticals, Inc. Methods for promoting the healing of cutaneous wounds and ulcers using compositions of α-D-glucans
US6323338B1 (en) * 1999-02-17 2001-11-27 Nurture, Inc. Method for concentrating β-glucan
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
US20020119164A1 (en) * 2000-08-18 2002-08-29 Shoji Uchiyama Use of agaricus blazei murill to prevent or treat skin and other disorders
US20040039057A1 (en) * 2000-09-19 2004-02-26 Perlmutter Alan L. Topical analgesic compositions containing aliphatic polyamines and methods of using same
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CA2434938C (en) 2001-01-16 2012-02-28 Sloan-Kettering Institute For Cancer Research Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
DE10106288A1 (en) * 2001-02-02 2002-09-05 Coty Bv Revitalizing active complex for the skin
NZ521894A (en) * 2001-02-15 2006-08-31 Adeka Corp Products containing beta-glucan
US20060233783A1 (en) * 2003-04-09 2006-10-19 Gomez Torres Harold A Topical composition in the form of a gel for treating skin burns
ES2413007T3 (en) * 2003-05-02 2013-07-15 Ceapro Inc. Improved extraction and purification procedure for beta (1-3) beta (1-4) cereal glucan
US20060121131A1 (en) * 2003-05-02 2006-06-08 Ceapro Inc. Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan
US20070224148A1 (en) * 2004-08-13 2007-09-27 Symrise Gmbh & Co. Kg Beta-(1,3)-Beta-(1,4)-Glucan as Carrier for Chemical Substances
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GB201020190D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucans
GB201020191D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan gels
CN110475817A (en) * 2017-03-28 2019-11-19 嘉吉公司 Easy water miscibility beta glucan suspension
CN113813367A (en) * 2021-09-30 2021-12-21 湖南天根乐微君科技有限公司 Composition and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573785A (en) * 1992-10-23 1996-11-12 R.I.T.A. Corporation Cosmetic component including water soluble fiber
US5783569A (en) * 1992-08-21 1998-07-21 Alpha-Beta Technology, Inc. Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5158772A (en) * 1991-09-23 1992-10-27 Davis Walter B Unique bacterial polysaccharide polymer gel in cosmetics, pharmaceuticals and foods
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
CN1081038C (en) * 1996-09-25 2002-03-20 格雷斯林克有限公司 Beta-glucan products and extration from cereals thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783569A (en) * 1992-08-21 1998-07-21 Alpha-Beta Technology, Inc. Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same
US5573785A (en) * 1992-10-23 1996-11-12 R.I.T.A. Corporation Cosmetic component including water soluble fiber

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Camano, Topical bactericidal composition e.g. for wound cleandsing containing-essential oil distilled, (WPIDS AN 97-309779 (28)), 1997.*
Estrada et al, Immunomodulatory activities of oat beta glucan in vitro and in vivo, Biosis (AN 128:191445, 1997. *
Osborne, Method and composition for cleaning wounds-comprises irrigating the wound with a surfactant, an antiseptic preservative mixed in an aqueous solution having minimal cytotoxity, WPIDS (97-489402 (45)), 1997. *
Osborne, Topical bactericidal composition, eg for wound cleansing containing essential oil distilled from Schinus Molle L. tree, effective e.g. agiainst Pseudomonas aeruginosa, (WPIDS AN 96-200652 )28)), 1996. *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157143A1 (en) * 1999-09-27 2003-08-21 Klein Barbara K. Immunostimulating coating for surgical devices
US7348021B2 (en) * 1999-09-27 2008-03-25 Brennen Medical, Llc Immunostimulating coating for surgical devices
US20050019876A1 (en) * 1999-10-01 2005-01-27 Incorporated Administrative Agency National Agriculture And Bio-Oriented Research Organization Cellulose produced by filamentous fungi
US6958227B2 (en) * 1999-10-01 2005-10-25 Incorporated Administrative Agency National Agriculture And Bio-Oriented Research Organization Cellulose produced by filamentous fungi
US20070104858A1 (en) * 2000-02-07 2007-05-10 Granate Seed Limited,a New Zealand corporation Process for extraction of beta-glucan from cereals and products obtained therefrom
US20060240083A1 (en) * 2000-03-30 2006-10-26 Brennen Medical, Llc Antimicrobial and immunostimulating composition
US20050031674A1 (en) * 2001-12-11 2005-02-10 Ceapro, Inc Cereal beta glucan compositions, methods of preparation and uses thereof
US8632798B2 (en) 2001-12-11 2014-01-21 Ceapro Inc. Cereal β glucan compositions, methods of preparation and uses thereof
DE10214507A1 (en) * 2002-04-02 2003-10-16 Beiersdorf Ag Use of topical composition comprising acarbose or its derivatives to prevent or treat degenerative skin conditions, especially skin irritation, skin inflammation, atopic eczema and neurodermatitis
US20100190872A1 (en) * 2005-05-05 2010-07-29 Sensient Flavors Inc. Production of beta-glucans and mannans
US8753668B2 (en) 2005-05-05 2014-06-17 Sensient Flavors Llc Production of beta-glucans and mannans
KR100832387B1 (en) * 2005-12-02 2008-05-26 주식회사 글루칸 Pharmaceutical Composition for Treatment of Wound and Dermatitis Comprising Glucan as Active Ingredient
JP2013155203A (en) * 2006-11-02 2013-08-15 Aureo Co Ltd Agent for promoting healing of living body
WO2010042991A1 (en) * 2008-10-15 2010-04-22 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
EP3130609A1 (en) * 2010-11-29 2017-02-15 Biotec Pharmacon ASA Composition comprising a gelling agent plus glucan
GB2536077A (en) * 2014-09-26 2016-09-07 Suavizantes Y Plastificantes Bituminosos S L Formulation for a cosmetic and personal care product and method for production thereof
CN109568652A (en) * 2018-12-26 2019-04-05 粤肽生物科技(珠海)有限公司 Promote the dressing composition of wound healing
US11384160B1 (en) 2021-07-30 2022-07-12 Tissue repair ltd Method of making a beta glucan compound
US11572420B1 (en) 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
US11912795B2 (en) 2021-07-30 2024-02-27 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
US11701451B1 (en) 2022-03-11 2023-07-18 Carbon Medical Technologies, Inc. Soft tissue filler and methods

Also Published As

Publication number Publication date
EP1024784A1 (en) 2000-08-09
EP1024784A4 (en) 2004-02-04
CA2304815A1 (en) 1999-05-06
WO1999021531A1 (en) 1999-05-06
US5980918A (en) 1999-11-09
JP2001520982A (en) 2001-11-06

Similar Documents

Publication Publication Date Title
US6168799B1 (en) β-D-glucan topical composition
CN112315882A (en) Soothing, repairing and moisturizing cream and preparation method thereof
US6242594B1 (en) Process for glucan preparation and therapeutic uses of glucan
CN109908015B (en) Anti-allergy repairing and moisturizing composition and preparation method and application thereof
US20100098794A1 (en) Topical anti-wrinkle and anti-aging moisturizing cream
JP2532817B2 (en) Cosmetic composition
JPH02501739A (en) steroid lotion
CN104814901B (en) One kind prevention striae of pregnancy gel and preparation method thereof
EP1480654A1 (en) Carbohydrate-based anti-wrinkle and tissue remodelling compounds
EP2347755A2 (en) Cosmetic compound with active ingredients for reducing wrinkles and/or reducing the depth of pores
NO320100B1 (en) Use of a combination of diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin disorders
WO2013160349A2 (en) Cosmetic composition comprising a phosphorylated oligosaccharide and a polysaccharide
JP2578341B2 (en) External preparation for skin
JP3213189B2 (en) Hyaluronic acid production promoter
Mora et al. Dermocosmetic applications of polymeric biomaterials
MXPA00003316A (en) &bgr;-D GLUCAN TOPICAL COMPOSITION
US8247390B2 (en) Modified hydrophilic polymers containing hydrophobic groups
JP3233504B2 (en) Cosmetics
CN111973471A (en) Cosmetic composition
JP2000095660A (en) Skin lotion
CN117562848A (en) Soothing and repairing essence and preparation method thereof
CN115282086A (en) Moisturizing composition and application thereof
JP2000212021A (en) Skin preparation for external use
CN117098527A (en) Cosmetic method and composition based on short-chain fructooligosaccharides and natural starch
AU716181B2 (en) Process for glucan preparation and therapeutic uses of glucan

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: BRENNEN MEDICAL, LLC, MINNESOTA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BRENNEN MEDICAL, INC.;REEL/FRAME:017325/0804

Effective date: 20060320

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: STELLEN MEDICAL, LLC, MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:STELLEN SCIENCES, LLC;REEL/FRAME:028687/0526

Effective date: 20120419

Owner name: STELLEN SCIENCES, LLC, MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:BRENNEN MEDICAL, LLC;REEL/FRAME:028687/0242

Effective date: 20120224